China Pharma Holdings, Inc. — Q1 2018 Form 10-Q
Reporting period: Three months ended March 31, 2018; interim financial statements are unaudited. The company manufactures and sells generic and branded pharmaceuticals and biochemical products primarily in China.
Financial performance and position
| Metric | Q1 2018 | Q1 2017 / prior balance-sheet date |
|---|---|---|
| Revenue | $3.616 million | $3.285 million; up 10.1% in U.S. dollars |
| Gross profit / margin | $1.054 million / 29.1% | $0.718 million / 21.9% |
| Operating loss | $0.141 million | $0.803 million |
| Net loss / loss per share | $0.293 million / $0.01 | $0.967 million / $0.02 |
| Comprehensive income (loss) | $1.381 million | $(0.487) million |
| Operating cash flow | $0.524 million | $0.010 million |
| Cash and cash equivalents | $2.468 million | $2.030 million at Dec. 31, 2017 |
| Total assets / liabilities | $62.127 million / $17.675 million | $59.953 million / $16.882 million at Dec. 31, 2017 |
- Management attributed the U.S.-dollar revenue increase mainly to RMB exchange-rate movements; revenue in RMB increased 2%, to RMB 23.0 million from RMB 22.6 million.
- Gross margin improved mainly because of higher general selling prices. Cost of revenue was $2.562 million, or about 71% of revenue, versus $2.567 million, or about 78%, a year earlier.
- Operating expenses were $1.194 million, down from $1.520 million, primarily reflecting bad-debt expense of $1,834 versus $360,063. General and administrative expense rose to $492,010; R&D expense was $22,213.
- Comprehensive income includes a $1.674 million foreign-currency translation gain; it does not change the reported net loss.
- Cash flow from investing was a $3,627 outflow and financing cash flow was a $157,316 outflow, mainly scheduled construction-loan principal payments. Cash increased by $437,821 in the quarter.
- Construction-loan debt totaled approximately $9.395 million, including $2.229 million current and $7.165 million non-current. The loan bears a floating rate; the most recently stated rate was 5.73%. Bankers’ acceptance notes payable were $1.185 million, matched by restricted cash of the same amount.
- Current assets were $13.615 million against current liabilities of $9.719 million. Cash held in China is considered indefinitely reinvested and is not expected to be available to the parent or shareholders.
Changes, outlook and risks
- Net loss narrowed year over year, mainly due to improved gross margin and substantially lower bad-debt expense. Management said collections improved; receivables more than 90 days past due were $1.7 million, down from $2.2 million at year-end.
- Receivables remain a significant risk: the allowance for doubtful accounts was $18.865 million, while reported net trade receivables were $2.475 million. The filing states that 78.9% of receivables were over 720 days old. Two customers represented 47.2% and 13.6% of accounts receivable.
- China’s generic-drug consistency evaluations and changing CFDA approval requirements may require additional trials, investment and time. Management terminated progression of certain pipeline products, reported no further pipeline development in Q1, and noted delays in product approvals. No specific earnings or revenue guidance was provided.
- Management expects operating cash flow to cover working capital and anticipated capital spending for the next 12 months, including consistency evaluations and formula acquisitions. It cautioned that changed circumstances could require additional financing or spending cuts; availability and terms of financing are not assured.
- The company had approximately $1.1 million of future payments to laboratories and service providers contingent on completion of contract phases, generally over about four years. CFDA approval is not assured; contractual remedies include refunds or applying payments to another formula.
- Other material risks include RMB conversion and remittance controls, PRC political, regulatory and economic conditions, customer collection delays, and supplier/customer concentration. Two suppliers accounted for 32.4% and 28.7% of raw-material purchases.
- Disclosure controls were deemed ineffective as of March 31, 2018 because of a material weakness involving insufficient personnel knowledgeable in U.S. GAAP financial reporting. Management nevertheless stated that the interim financial statements were fairly stated in all material respects.
Key facts for investors to verify
- Assess the aging, recoverability and allowance coverage of receivables, especially balances over 720 days and exposure to the two largest receivable customers.
- Track operating cash generation against scheduled loan repayments, restricted cash, formula-related commitments and the company’s ability to fund operations from cash held in China.
- Monitor gross-margin sustainability, RMB-to-U.S.-dollar effects and progress, costs and approval outcomes for generic-drug evaluations and pipeline products.
- Review remediation of the material weakness in U.S. GAAP reporting controls and any subsequent financing needs.
- Check the tax note’s period labels: its income-tax table identifies periods as three months ended March 31, 2017 and 2016, while the financial statements otherwise compare 2018 and 2017; the filing text does not clearly reconcile this discrepancy.